Pfizer Stock Price, News & Analysis

Pfizer (NYSE:PFE) on December 16, 2025 reaffirmed full‑year 2025 adjusted diluted EPS guidance and revised 2025 revenue to approximately $62.0 billion, while providing full‑year 2026 guidance. Key 2026 guidance: revenues $59.5–$62.5 billion and adjusted diluted EPS $2.80–$3.00. Pfizer expects COVID‑19 product revenues of ~$5.0 billion in 2026 (about $1.5 billion lower than 2025) and an additional ~$1.5 billion negative impact from loss of exclusivity. 2026 adjusted SI&A and R&D combined are expected at $23.0–$25.0 billion, and the effective adjusted tax rate is expected to rise to ~15% from ~11% in 2025. A live webcast and call were scheduled for December 16, 2025 at 8:00 AM ET.

Pfizer (NYSE: PFE) announced its board approved a $0.43 per share quarterly cash dividend for first-quarter 2026. The dividend is payable March 6, 2026 to shareholders of record at the close of business on January 23, 2026. This payment will mark Pfizer's 349th consecutive quarterly dividend, continuing the company's long-running shareholder distribution record.

Pfizer (NYSE: PFE) reported Phase 3 HER2CLIMB-05 results showing TUKYSA (tucatinib) added to trastuzumab and pertuzumab as first-line maintenance reduced risk of progression or death by 35.9% (HR 0.641; 95% CI 0.514-0.799; p<0.0001) versus trastuzumab and pertuzumab alone.

Median progression-free survival was 24.9 months with TUKYSA vs 16.3 months with placebo, an extension of 8.6 months. PFS benefit was consistent across prespecified subgroups. Overall survival was not mature (≈20% of events) and showed a numerical trend favoring TUKYSA. Safety was generally consistent with known profiles but included a higher rate of asymptomatic Grade ≥3 liver transaminase elevations, typically manageable with dose changes or discontinuation. TUKYSA is not approved for first-line use; results will be discussed with regulators.

Fosun Pharma (PFE) subsidiary Yao Pharma and Pfizer (PFE) entered an exclusive global collaboration and license agreement on December 9, 2025.

Yao Pharma will complete a Phase 1 trial of oral small‑molecule GLP‑1R agonist YP05002 in Australia and grants Pfizer an exclusive worldwide license to develop, manufacture and commercialize YP05002 and related oral small‑molecule GLP‑1R agonists for all human and veterinary indications.

Financial terms include an upfront payment of $150 million, up to $1.935 billion in development/regulatory/commercial milestone payments, plus tiered royalties on sales.

Pfizer (NYSE: PFE) entered an exclusive global collaboration and license agreement with YaoPharma for YP05002, a Phase 1 small‑molecule GLP‑1 receptor agonist for chronic weight management, announced December 9, 2025. YaoPharma will finish the ongoing Phase 1 trial and granted Pfizer rights to develop, manufacture and commercialize YP05002 worldwide.

Financial terms include a $150 million upfront payment and up to $1.935 billion in potential development, regulatory and commercial milestone payments, plus tiered royalties if approved. Pfizer plans combination studies with its GIPR antagonist PF‑07976016 (Phase 2).

Pfizer (NYSE: PFE) reported Phase 3 BASIS results showing HYMPAVZI (marstacimab) reduced mean treated annualized bleeding rate (ABR) by 93% versus on‑demand bypassing agents (1.39 vs. 19.78; p<0.0001) in adults and adolescents with hemophilia A or B with inhibitors.

In 48 patients during a 12‑month active treatment phase, median ABR was 0 on HYMPAVZI; dosing was a 300 mg SC loading dose then 150 mg weekly. Quality‑of‑life scores improved and no deaths or thromboembolic events were reported. One treatment‑related serious adverse event led to discontinuation. Data were presented at ASH and published in Blood and have been submitted to the FDA and EMA.

Pfizer (NYSE: PFE) will host a conference call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025 to provide its full-year 2026 financial guidance. The live webcast will be available at www.pfizer.com/investors, with registration open beginning December 1, 2025. Dial-in is available at 800-456-4352 (U.S./Canada) or 785-424-1086 (international) using passcode 71848. A transcript and replay will be posted on the investor site within 24 hours and remain accessible for at least 90 days.

Pfizer (NYSE: PFE) announced that the U.S. FDA approved PADCEV plus Keytruda as a perioperative (neoadjuvant then adjuvant) treatment for adult cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) on November 21, 2025.

Approval was based on Phase 3 EV-303 (KEYNOTE-905) data showing 60% lower risk of recurrence/progression/death (EFS HR=0.40; p<0.0001) and a 50% lower risk of death (OS HR=0.50; p=0.0002) versus surgery alone; median EFS and OS are not reached for the combination. Grade ≥3 adverse events occurred in 71.3% of combination patients versus 45.9% for surgery alone.

Pfizer (NYSE: PFE) completed its acquisition of Metsera on November 13, 2025, buying all outstanding Metsera shares for $65.60 per share in cash and an enterprise value of approximately $7.0 billion.

The deal includes a contingent value right (CVR) of up to $20.65 per share tied to three clinical and regulatory milestones. Metsera is now a Pfizer subsidiary and its common stock will cease trading on NASDAQ. Key assets transferred include MET-097i (weekly/monthly GLP-1 RA entering Phase 3), MET-233i (monthly amylin analog in Phase 1), an oral GLP-1 RA in Phase 1, and preclinical hormone therapeutics.

Pfizer expects the transaction to be dilutive through 2030 and will update financial outlook with 2026 guidance later this year.